70 related articles for article (PubMed ID: 21933913)
1. Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanoma.
Huber C; Bouchardy C; Schaffar R; Neyroud-Caspar I; Vlastos G; Le Gal FA; Rapiti E; Benhamou S
Cancer Prev Res (Phila); 2012 Jan; 5(1):82-8. PubMed ID: 21933913
[TBL] [Abstract][Full Text] [Related]
2. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
3. Risk of second primary malignancies in women with papillary thyroid cancer.
Canchola AJ; Horn-Ross PL; Purdie DM
Am J Epidemiol; 2006 Mar; 163(6):521-7. PubMed ID: 16421240
[TBL] [Abstract][Full Text] [Related]
4. The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries).
Crocetti E; Guzzinati S; Paci E; Falcini F; Zanetti R; Vercelli M; Rashid I; De Lisi V; Russo A; Vitarelli S; Ferretti S; Mangone L; Cesaraccio R; Tumino R; Pannozzo F
Melanoma Res; 2008 Jun; 18(3):230-4. PubMed ID: 18477899
[TBL] [Abstract][Full Text] [Related]
5. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
Spanogle JP; Clarke CA; Aroner S; Swetter SM
J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
[TBL] [Abstract][Full Text] [Related]
6. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation.
Tuohimaa P; Pukkala E; Scélo G; Olsen JH; Brewster DH; Hemminki K; Tracey E; Weiderpass E; Kliewer EV; Pompe-Kirn V; McBride ML; Martos C; Chia KS; Tonita JM; Jonasson JG; Boffetta P; Brennan P
Eur J Cancer; 2007 Jul; 43(11):1701-12. PubMed ID: 17540555
[TBL] [Abstract][Full Text] [Related]
7. Risk of second breast cancer according to estrogen receptor status and family history.
Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
[TBL] [Abstract][Full Text] [Related]
8. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001.
Soerjomataram I; Louwman WJ; de Vries E; Lemmens VE; Klokman WJ; Coebergh JW
Breast Cancer Res Treat; 2005 Sep; 93(1):91-5. PubMed ID: 16184464
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of second cancer among patients with ovarian borderline tumors.
Bouchardy C; Fernandez S; Merglen A; Usel M; Fioretta G; Rapiti E; Schubert H; Pelte MF; Chappuis PO; Vlastos G
Gynecol Oncol; 2008 May; 109(2):210-4. PubMed ID: 18377966
[TBL] [Abstract][Full Text] [Related]
10. The association between malignant melanoma and noncutaneous malignancies.
Wu YH; Kim GH; Wagner JD; Hood AF; Chuang TY
Int J Dermatol; 2006 May; 45(5):529-34. PubMed ID: 16700785
[TBL] [Abstract][Full Text] [Related]
11. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
Schaapveld M; Visser O; Louwman MJ; de Vries EG; Willemse PH; Otter R; van der Graaf WT; Coebergh JW; van Leeuwen FE
J Clin Oncol; 2008 Mar; 26(8):1239-46. PubMed ID: 18323547
[TBL] [Abstract][Full Text] [Related]
12. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer.
Thellenberg C; Malmer B; Tavelin B; Grönberg H
J Urol; 2003 Apr; 169(4):1345-8. PubMed ID: 12629357
[TBL] [Abstract][Full Text] [Related]
13. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
14. The risk of oesophageal cancer is not affected by a diagnosis of breast cancer.
Cooper SC; Croft S; Day R; Thomson CS; Trudgill NJ
Eur J Cancer Prev; 2010 May; 19(3):182-5. PubMed ID: 20145541
[TBL] [Abstract][Full Text] [Related]
15. The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma.
Schenk M; Severson RK; Pawlish KS
Cancer; 1998 May; 82(9):1672-6. PubMed ID: 9576287
[TBL] [Abstract][Full Text] [Related]
16. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.
Brennan P; Coates M; Armstrong B; Colin D; Boffetta P
Br J Cancer; 2000 Apr; 82(7):1344-7. PubMed ID: 10755412
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment.
Rubino C; Shamsaldin A; Lê MG; Labbé M; Guinebretière JM; Chavaudra J; de Vathaire F
Breast Cancer Res Treat; 2005 Feb; 89(3):277-88. PubMed ID: 15754127
[TBL] [Abstract][Full Text] [Related]
18. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.
Balamurugan A; Rees JR; Kosary C; Rim SH; Li J; Stewart SL
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S69-77. PubMed ID: 22018070
[TBL] [Abstract][Full Text] [Related]
19. Melanoma and additional primary cancers.
Retsas S; Mohith A; Bell J; Horwood N; Alexander H
Melanoma Res; 2000 Apr; 10(2):145-52. PubMed ID: 10803715
[TBL] [Abstract][Full Text] [Related]
20. Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008.
van der Leest RJ; Liu L; Coebergh JW; Neumann HA; Mooi WJ; Nijsten T; de Vries E
Br J Dermatol; 2012 Dec; 167(6):1321-30. PubMed ID: 22759226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
